Neurocrine Biosciences is joining the M&A bonanza with a $2.9 billion takeover of profitable rare disease drugmaker Soleno Therapeutics. Neurocrine will pay $53 per share,

It’s no secret that cancer drug development is full of bandwagons. Companies see a promising target, and crowd around it (see PD-1xVEGF or HER2 for

Syneron Bio said it raised a Series B round worth $150 million, which it will use to back the development of a drug class that’s

Eli Lilly has published a video about how medicines affect lives to mark its 150th anniversary and the arrival of college basketball stars in its

VML Health has published a report about 10 trends defining the future of healthcare, making the case that pharma marketers must adapt to patients shifting